Previous Article | Next Article ![]()
Journal of Clinical Microbiology, June 1999, p. 1852-1857, Vol. 37, No. 6
Départements de
Microbiologie-Immunologie et de Pédiatrie,
Received 26 October 1998/Returned for modification 7 December
1998/Accepted 15 March 1999
The line blot assay, a gene amplification method that combines PCR
with nonisotopic detection of amplified DNA, was evaluated for its
ability to detect human papillomavirus (HPV) DNA in genital specimens.
Processed samples were amplified with biotin-labeled primers for HPV
detection (primers MY09, MY11, and HMB01) and for
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Nonisotopic Detection and Typing of Human
Papillomavirus DNA in Genital Samples by the Line Blot Assay

-globin detection
(primers PC03 and PC04). Amplified DNA products were hybridized by a
reverse blot method with oligonucleotide probe mixtures fixed on a
strip that allowed the identification of 27 HPV genotypes. The line
blot assay was compared to a standard consensus PCR test in which HPV
amplicons were detected with radiolabeled probes in a dot blot assay.
Two hundred fifty-five cervicovaginal lavage specimens and cervical
scrapings were tested in parallel by both PCR tests. The line blot
assay consistently detected 25 copies of HPV type 18 per run. The
overall positivity for the DNA of HPV types detectable by both methods
was 37.7% (96 of 255 samples) by the line blot assay, whereas it was
43.5% (111 of 255 samples) by the standard consensus PCR assay. The
sensitivity and specificity of the line blot assay reached 84.7% (94 of 111 samples) and 98.6% (142 of 144 samples), respectively. The
agreement for HPV typing between the two PCR assays reached 83.9% (214 of 255 samples). Of the 37 samples with discrepant results, 33 (89%) were resolved by avoiding coamplification of
-globin and modifying the amplification parameters. With these modifications, the line blot
assay compared favorably to an assay that used radiolabeled probes. Its
convenience allows the faster analysis of samples for large-scale
epidemiological studies. Also, the increased probe spectrum in this
single hybridization assay permits more complete type discrimination.
*
Corresponding author. Mailing address:
Département de Microbiologie et Infectiologie, Centre Hospitalier
de l'Université de Montréal, Campus Notre-Dame, 1560 Sherbrooke est, Montréal, Québec H2L 4M1, Canada. Phone:
514-281-6000, ext. 5162. Fax: 514-896-4607. E-mail:
coutleef{at}sympatico.ca.
Present address: Department of Epidemiology, Johns Hopkins
University School of Hygiene and Public Health, Baltimore, MD 21205.
The Canadian Women's HIV study group includes the following
investigators: Catherine Hankins, Normand Lapointe, John Gill, Barbara
Romanowski, Stephen Shafran, Rob Grimshaw, David Haase, Wally Schlech,
Stephen Landis, John Sellors, Fiona Smaill, Francois Beaudoin, Marc
Boucher, Ngoc Bui, Michel Chateauvert, Manon Coté, François
Coutlée, Douglas Dalton, Gretty Deutsch, Julian Falutz, Diane
Francoeur, Lisa Hallman, Lina Karayan, Louise Labrecque, Richard
Lalonde, Christiane Lavoie, Catherine Lounsbury, John Macleod, Nicole
Marceau, Grégoire Noel, Grégoire Piché, Jean-Pierre Routy, Pierre Simard, Christina Smeja, Graham Smith, Pierre-Paul Tellier, Emil Toma, Garry Garber, Garry Victor, Louise Coté, Édith Guilbert, Michel Morissette, Hélène Senay,
Sylvie Trottier, Phil Berger, Lisa Friedland, Donna Keystone, Joan
Murphy, Anne Phillips, Marion Powell, Anita Rachlis, Pat Rockman,
Irving Salit, Cheryl Wagner, Sharon Walmsey, Kurt Williams, Ian Bowmer,
Rory Windrim, Roger Sandre, Penny Ballem, David Burdge, Brian Conway, Marianne Harris, Deborah Money, Julio Montaner, and Janice Veenhuizen.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|